Taysha Gene Therapies
TSHA
127 hedge funds and large institutions have $232M invested in Taysha Gene Therapies in 2025 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 31 reducing their positions, and 25 closing their positions.
1,957% more call options, than puts
Call options by funds: $144K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
0.33% less ownership
Funds ownership: 81.72% → 81.39% (-0.33%)
3% less funds holding
Funds holding: 131 → 127 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
20% less capital invested
Capital invested by funds: $290M → $232M (-$57.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$16.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.64M |
| 3 |
Millennium Management
New York
|
+$2.71M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.49M |
| 5 |
SCM
Superstring Capital Management
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.65M |
| 2 |
VA
VR Adviser
New York
|
-$5.58M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.42M |
| 4 |
JP Morgan Chase
New York
|
-$2.74M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.53M |
TSHA Hedge Fund Activity: Q1 2025 in Review
127 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2025, worth a combined $232M — down 20% from $290M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TSHA and 21 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 38 added.
The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.65M sold.
- 127 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2025, down from 131 in Q4 2024.
- Funds reported $232M of Taysha Gene Therapies stock for Q1 2025, down 20% quarter-over-quarter.
- 21 funds opened new Taysha Gene Therapies positions in Q1 2025 and 25 closed out, a net change of -4 holders.
- The largest Taysha Gene Therapies buyer in Q1 2025 was RTW Investments, an estimated $16.9M added.
- The largest Taysha Gene Therapies seller in Q1 2025 was Adage Capital Partners, an estimated $8.65M sold.
Based on aggregated 13F filings for Q1 2025.